CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 217-228 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2021CrossrefDirectly related1 citations

CAR-T-ICI: Kombinasi chimeric antigen receptor T-cell dengan immune checkpoint inhibitor anti PD-1 selaku pilihan terapi terbaru kanker kolorektal

Imam Hermansyah; Eddy Zulfikar

Jul 12, 2021JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia

2021CrossrefDirectly related154 citations

Engineered Cytokine Signaling to Improve CAR T Cell Effector Function

Matthew Bell; Stephen Gottschalk

Jun 4, 2021Frontiers in Immunology

2021OpenAlexDirectly related2,948 citations

CAR-T cell therapy: current limitations and potential strategies

Robert C. Sterner; Rosalie M. Sterner; Rosalie M. Sterner; Rosalie M. Sterner

Apr 6, 2021Blood Cancer Journal

2021OpenAlexDirectly related279 citations

Promises and challenges of adoptive T-cell therapies for solid tumours

Matteo Morotti; Ashwag Albukhari; Abdulkhaliq Alsaadi; Mara Artibani; James D. Brenton; Stuart M. Curbishley; Tao Dong; Michael L. Dustin; Zhiyuan Hu; Nicholas McGranahan; Martin L. Miller; Laura Santana-Gonzalez; Leonard W. Seymour; Tingyan Shi; Peter Van Loo; Christopher Yau; Helen White; Nina Wietek; David N. Church; David C. Wedge; Ahmed A. Ahmed

Mar 29, 2021British Journal of Cancer

2021OpenAlexDirectly related287 citations

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu; Yali Zhou; Mingming Zhang; Wengang Ge; Yi Li; Li Yang; Guoqing Wei; Lu Han; Hao Wang; Shuhui Yu; Yi Chen; Yanbin Wang; Xiaohong He; Xingwang Zhang; Ming Gao; Jingjing Yang; Xiuju Li; Jiangtao Ren; He Huang

Feb 24, 2021Clinical Cancer Research

2021CrossrefDirectly related229 citations

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer

May Daher; Katayoun Rezvani

Jan 1, 2021Cancer Discovery

2020OpenAlexDirectly related1,879 citations

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang; Javier Muñoz; André Goy; Frederick L. Locke; Caron A. Jacobson; Brian T. Hill; John M. Timmerman; Houston Holmes; Samantha Jaglowski; Ian W. Flinn; Peter A. McSweeney; David B. Miklos; John M. Pagel; Marie José Kersten; Nöel Milpied; Henry C. Fung; Max S. Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M. Rossi; Rajul K. Jain; Arati V. Rao; Patrick M. Reagan

Apr 1, 2020New England Journal of Medicine

2019CrossrefDirectly related14 citations

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Naoki Hosen

Dec 15, 2019Cancers

2019OpenAlexDirectly related161 citations

Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials

Seshu Tyagarajan; Tom Spencer; Jonathan Smith

Nov 28, 2019Molecular Therapy — Methods & Clinical Development

2019OpenAlexDirectly related414 citations

Engineered T Cell Therapy for Cancer in the Clinic

Lijun Zhao; Yu Cao

Oct 11, 2019Frontiers in Immunology

2019OpenAlexDirectly related250 citations

Genetically engineered T cells for cancer immunotherapy

Dan Li; Xue Li; Weilin Zhou; Yong Huang; Xiao Liang; Lin Jiang; Xiao Yang; Jie Sun; Zonghai Li; Weidong Han; Wei Wang

Sep 19, 2019Signal Transduction and Targeted Therapy

2019CrossrefDirectly related19 citations

Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T‐cell therapy for chronic lymphocytic leukemia

Steven M. Bair; David L. Porter

May 1, 2019American Journal of Hematology